Stocco CO, Lau LF, Gibori G (2002) A calcium/calmodulin-dependent activation of ERK1/2 mediates JunD phosphorylation and induction of nur77 and 20alpha-hsd genes by prostaglandin F2alpha in ovarian cells. J Biol Chem 277, 3293-302 11719525

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T203-p - ERK1 (rat) ▲

Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'granulosa, luteal' Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PGE2a increase W-7 PGE2a inhibit treatment-induced increase BAPTA-AM PGE2a inhibit treatment-induced increase

Y205-p - ERK1 (rat) ▲

Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'granulosa, luteal' Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PGE2a increase W-7 PGE2a inhibit treatment-induced increase BAPTA-AM PGE2a inhibit treatment-induced increase

T183-p - ERK2 (rat) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'granulosa, luteal' Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PGE2a increase W-7 PGE2a inhibit treatment-induced increase BAPTA-AM PGE2a inhibit treatment-induced increase

Y185-p - ERK2 (rat) ▲

Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'granulosa, luteal' Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PGE2a increase W-7 PGE2a inhibit treatment-induced increase BAPTA-AM PGE2a inhibit treatment-induced increase

S100-p - JunD (rat) ▲

Modsite: LGLLKLAsPELERLI SwissProt Entrez-Gene Orthologous residues JunD (human): S100‑p, JunD (mouse): S100‑p, JunD (rat): S100‑p, JunD (cow): S102‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'granulosa, luteal' Cellular systems studied:  primary cells Species studied:  rat Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE ERK1 (rat) phospho-antibody, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme KINASE ERK2 (rat) phospho-antibody, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PGE2a increase BAPTA-AM PGE2a inhibit treatment-induced increase W-7 PGE2a inhibit treatment-induced increase PD98059 PGE2a inhibit treatment-induced increase SB203580 PGE2a augment treatment-induced increase Downstream Regulation Effect of modification (process):  transcription, induced